MINIMALLY INVASIVE LUNG ADENOCARCINOMA
Clinical trials for MINIMALLY INVASIVE LUNG ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new MINIMALLY INVASIVE LUNG ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for MINIMALLY INVASIVE LUNG ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a new drug combo shrink tough lung tumors?
Disease control OngoingThis study tests whether adding the drug veliparib to standard chemotherapy and radiation helps people with stage III lung cancer that can't be removed by surgery. About 53 adults took part to find the best dose and see if the combination slows cancer growth. The goal is to impro…
Matched conditions: MINIMALLY INVASIVE LUNG ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 04:30 UTC
-
New combo therapy aims to boost lung cancer survival
Disease control OngoingThis study tests whether adding an immunotherapy drug (nivolumab) to precise, high-dose radiation (SABR) helps keep early-stage non-small cell lung cancer from coming back. About 140 people with stage I-IIA or recurrent lung cancer will be randomly assigned to get radiation alone…
Matched conditions: MINIMALLY INVASIVE LUNG ADENOCARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 04:16 UTC
-
Immunotherapy duo takes on 50+ rare cancers in major trial
Disease control OngoingThis phase 2 trial tests a combination of two immunotherapy drugs (nivolumab and ipilimumab) in over 800 people with more than 50 types of rare cancers. The goal is to see if this treatment can shrink tumors by helping the immune system attack cancer cells. The study is for patie…
Matched conditions: MINIMALLY INVASIVE LUNG ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New cocktail for inoperable lung cancer shows promise in early trial
Disease control OngoingThis study tested a three-part treatment for people with stage III lung cancer that cannot be removed by surgery. The treatment combined standard chemotherapy (cisplatin and etoposide) with radiation, followed by two additional drugs (docetaxel and bevacizumab) to try to kill mor…
Matched conditions: MINIMALLY INVASIVE LUNG ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 14, 2026 12:06 UTC